Trials (IRCCS Centro di Riferimento Oncologico della Basilicata): Revision history

15 December 2025

• curprev 12:1912:19, 15 December 2025‎ Francine talk contribs‎ 31,125 bytes +234‎ No edit summary undo

6 December 2025

• curprev 12:4112:41, 6 December 2025‎ Lucas talk contribs‎ m 30,891 bytes +1,701‎ Update categories. undo

4 December 2025

• curprev 00:5800:58, 4 December 2025‎ Larysse talk contribs‎ 29,190 bytes +47‎ No edit summary undo

2 December 2025

• curprev 13:5913:59, 2 December 2025‎ Lucas talk contribs‎ m 29,143 bytes +90‎ Update categories. undo

4 December 2023

• curprev 17:0417:04, 4 December 2023‎ Francine talk contribs‎ 29,053 bytes +29,053‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to IRCCS Centro di Riferimento Oncologico della Basilicata page '''NCTID''': NCT03268954 '''Title''': Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) '''Study Summary''': The purpose of this study is to determine..."